BACKGROUND The efficacy of a non-prescription drug to support weight loss programs has yet to be compared. This clinical trial investigates the comparability of orlistat 60 milligram (mg) and polyglucosamine. METHODS Sixty-four overweight or obese subjects were included in a two-center double-blind study. One center was in Germany [center 1] and the other was in Italy [center 2]. The subjects...

Sir, We welcome the interest of MacLaughlin and Macdougall in the use of the gastrointestinal lipase inhibitor orlistat in patients with chronic kidney disease (CKD). We previously reported the rapid, non-recoverable decline of renal function in a patient with diabetic nephropathy, that coincided temporally with the successful use of orlistat for weight reduction [1]. There was histological evi...

Abiraterone acetate for metastatic castration-resistant prostate cancer is an acetylated prodrug to be hydrolyzed abiraterone. known by pancreatic cholesterol esterase secreted into the intestinal lumen. This study aimed investigate possibility that arylacetamide deacetylase (AADAC) expressed in enterocytes contributes hydrolysis of abiraterone based on its substrate preference. hydrolase activ...

Orlistat (Xenical) (Fig. 1), a highly lipophilic tetrahydro derivative of lipstatin, is an inhibitor of gastric and pancreatic lipases required for the hydrolysis of dietary fat (triacylglycerols) in the gastrointestinal tract into free fatty acids and monoacylglycerols. A major contributing factor to the development and maintenance of obesity is excessive intake of dietary triglycerides. Inhib...

BACKGROUND Obesity and overweight are major public health problems. Various factors, such as daily nutritional habits, physical inactivity, and genetic, are related to the prevalence of obesity. Recently, it was revealed that the gut microflora may also play an important role in weight management. Thus, this study aimed to determine the anti-obesity effects of Lactobacillus casei strain Shirota...

UNLABELLED OBJECTIVE; Weight loss improves glycemic control, lipid profiles, and blood pressure in patients with type 2 diabetes. However, successful long-term weight loss is difficult for these patients, particularly those treated with insulin. The aim of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on weight loss, glycemic control, and cardiovascular r...

OBJECTIVE To measure the association between orlistat and acute liver injury. DESIGN Self controlled case series study. SETTING Population based primary care setting, United Kingdom. PARTICIPANTS 94,695 patients receiving orlistat and registered in the UK Clinical Practice Research Datalink and linked with Hospital Episode Statistics data between 1999 and 2011. MAIN OUTCOME MEASURE Rela...

Giardiasis, a gastrointestinal disease caused by Giardia duodenalis, is currently treated mainly with nitroimidazoles, primarily metronidazole (MTZ). Treatment failure rates of up to 20 percent reflect the compelling need for alternative treatment options. Here, we investigated whether orlistat, a drug approved to treat obesity, represents a potential therapeutic agent against giardiasis. We co...

Previous meta-analyses investigating blood pressure effects of anti-obesity drugs have included studies using non-licensed doses, but not data from head-to-head studies. Furthermore, although diabetes is an important comorbidity in obesity, variation in blood pressure effects across diabetes status has not been investigated. The objective of this study was to estimate the effects on systolic (S...

BACKGROUND Obesity is closely related to type 2 diabetes mellitus, and weight reduction is an important part of the care delivered to obese persons with diabetes. The objective of this review was to assess the efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes. METHODS A systematic review of the literature was performed, and studies were included if pharmacotherapy was...